Has Paul Cohen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $160,984 in general payments to Paul Cohen, MD across 55 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Cohen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Cohen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Cohen, MD

Cardiovascular Disease · New York, NYNPI 1649306226

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $104,847 of the $160,984 with a category attached, or 65.1%. Amarin Pharma, Inc. accounts for 99.1% of it on its own, with 3 other manufacturers making up the rest. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$160,984in general payments, 2019–2025

Across 55 payments — averaging $2926.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amarin Pharma, Inc.$160K
Eli Lilly$1K
Regeneron$359
Redhill Biopharma Inc.$34

$708,000in research payments, 2019–2025

Across 9 payments — averaging $78,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$708K

What the payments were for

Consulting fees$1,0501%
Speaking & faculty fees$104,84765%
Travel & lodging$54,24734%
Food & beverage$8411%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amarin Pharma, Inc.	50	$159,541
Eli Lilly	1	$1,050
Regeneron	2	$359
Redhill Biopharma Inc.	2	$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vascepa$158,850

How this compares

$160,984 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$3,583

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metoprolol Succinate	20	$353
Atorvastatin Calcium	13	$300
Rosuvastatin Calcium	23	$96
Losartan Potassium	16	$83
Hydrochlorothiazide	13	$32

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

Roger HajjarNew York$5.2M
Gregg StoneNew York$2M
Philippe GenereuxNew York$1.3M
Adam RosenbluthNew York$1.1M
Megha PrasadNew York$813K
Eyal HerzogNew York$645K
Nisha JhalaniNew York$443K
Roxana MehranNew York$432K
Howard WeintraubNew York$328K
Anuradha Lala-TrindadeNew York$324K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →